Intranasal Administration of Chitosan-Coated Nanostructured Lipid Carriers Loaded with GDNF Improves Behavioral and Histological Recovery in a Partial Lesion Model of Parkinson's Disease

• DOI: 10.1166/jbn.2016.2313
• Publication Date: 2016-11-04T10:59:13Z
• Authors: O. Gartziandia; E. Herrán; J. A. Ruiz-Ortega; C. Miguelez; M. Igartua; J. V. Lafuente; J. L. Pedraz; L. Ugedo; R. M. Hernández
• Keywords: Male; 0301 basic medicine; Drug Carriers; Behavior, Animal; Parkinson Disease; Lipids; PC12 Cells; Corpus Striatum; Nanostructures; Rats; 3. Good health; Rats, Sprague-Dawley; Disease Models, Animal; 03 medical and health sciences; Animals; Glial Cell Line-Derived Neurotrophic Factor; Particle Size; Administration, Intranasal

Parkinson's disease (PD) is the second most frequent neurodegenerative disorder, but current therapies are only symptomatic. A promising alternative to address process use of neurotrophic factors, such as glial cell-derived factor (GDNF). However, its clinical has been limited due short half-life and rapid degradation after in vivo administration, addition difficulties crossing blood-brain barrier (BBB). This a limiting brain drug development, making future progression neurotherapeutics difficult. In past few years, intranasal delivery appeared an non-invasive administration route bypass BBB target drugs directly CNS. Thus, aim this work was study neuroprotective effect intranasally administered GDNF, encapsulated chitosan-coated nanostructured lipid carrier (CS-NLC-GDNF), 6-OHDA partially lesioned rat model. The developed CS-NLC-GDNF showed particle size approximately 130 nm high encapsulation efficiency. vitro PC-12 cells demonstrated ability GDNF protect these against toxin. After two weeks daily treatments, achieved behavioral improvement rats, well significant both density TH+ fibres striatum neuronal SN. it can be concluded that nose-to-brain could therapy for treatment PD.